Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7
about
Single-cell analysis tools for drug discovery and developmentDetecting Antigen-Specific T Cell Responses: From Bulk Populations to Single CellsDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Bioorthogonal cleavage and exchange of major histocompatibility complex ligands by employing azobenzene-containing peptidesHLA-F complex without peptide binds to MHC class I protein in the open conformer form.Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of ImmunodominanceIdentification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cellsIdentification of the core regulators of the HLA I-peptide binding processCytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypesCombinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.Differential regulation of effector- and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells.Evolution of MHC-based technologies used for detection of antigen-responsive T cellsInfluence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads.Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimersHigh-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes.Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.Broadening the repertoire of melanoma-associated T-cell epitopes.Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I MoleculesApplication of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.Viral acute lower respiratory infections impair CD8+ T cells through PD-1Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes.The CD8 T-cell response against murine gammaherpesvirus 68 is directed toward a broad repertoire of epitopes from both early and late antigens.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.Simultaneous detection of many T-cell specificities using combinatorial tetramer staining.Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition.MHC-based detection of antigen-specific CD8+ T cell responses.Photochemical approaches to T-cell activation.MHC-peptide tetramers for the analysis of antigen-specific T cells.Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development.The cancer antigenome.TCR repertoires of intratumoral T-cell subsets.Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.
P2860
Q26775754-14AE0721-7A40-4F9E-951A-CB1829D67CF2Q26798132-6AE71B72-04C9-4825-BA29-415702942C13Q26830857-3B8E03F3-9100-4C86-A895-8C9786C7F49CQ27695736-E2B6F867-7B90-49B1-8DA5-2A0C56463523Q28282824-785E25C2-37A0-4FD1-8D91-87B5087AC397Q28552025-7CC13505-8304-4979-9DA5-84E02100B6D1Q28710385-1C8AE305-A428-45F7-8CBF-7FA78A587D5CQ29048598-470CFFD7-E1D8-4DE9-AF33-286CB6B18DBEQ30543634-A4282D06-B841-45F5-939F-97B0AAF8BCD7Q30550855-7F8FFA5D-2517-46CC-91E7-492CAAE2B9F7Q33545222-10E4B579-CFC7-41E7-A8A7-5A50F39B4ABEQ33607055-EDA302C3-F392-4980-95F0-47482A7AA051Q33688931-2AB07022-05F5-42F6-A3E5-D8495F0CF339Q33788685-93790BA4-5DA9-4BBF-A873-E87CE00D9AD3Q33934932-5FCAECB4-92A6-490E-8BF4-BF366467AD39Q33952256-8E1B681E-046F-4BF3-AB06-B36F25C57649Q33995557-728A3352-2A81-4A40-ACA1-EDDB82AC7BE1Q34516547-38C4AB2E-4866-40A6-8537-B02267A93E03Q34529083-244F394F-A75D-4E72-8645-6640D2B3031DQ34988072-C81CE627-DB5D-4F1A-81DE-11B16E5A48BEQ35546276-A5010D2B-5F85-4277-ADA9-F5A038D5AAC1Q35786206-1ABBABFD-BEAC-4C19-855C-57B6D2AF2A99Q35817394-05D85280-6325-48CF-ACDC-D1B47DDB2F9CQ36129102-F0165D8E-708D-4084-A2AF-861CD4AE3CD0Q36444798-9F7EF154-23D5-4396-BD95-6634F7B5BF6DQ36633085-3A28D05A-0124-4D6E-ABBB-F768F6F73C07Q36994605-150AA297-6711-4D78-9B23-797AA889BCFBQ37173548-95A56F6F-0789-4D38-9306-08A4100A8978Q37287754-E259BE65-6B40-4DB5-AFF1-884C20FF2C59Q37316344-EAFB2C6F-64FD-443D-A28C-A41299BD8287Q37469949-87F8AB19-32CC-4EF4-9F08-FAD6DB258FB7Q37696988-DB45E3A7-5A27-4BC9-85CD-B3347C5C0020Q37734571-0F72C7D2-6D3E-4721-9727-01277E1C9AA0Q37771944-828B627B-B507-472D-A34E-5154188ADE93Q37844333-1930DCAC-09C8-461A-939A-6899068564A6Q38069075-11EBD7A6-3501-4809-851D-41F0A5D74164Q38170497-E350D42F-DE6A-4DD3-8A69-EBACD1167CE6Q38265356-AD787B4C-FC0D-48E7-8559-44850B36981EQ38588894-DAAEDEFA-D9E4-412B-8EEA-9CF0391BBE3DQ38871209-6DC72184-221C-434B-AD73-ACF536126E59
P2860
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@ast
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@en
type
label
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@ast
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@en
prefLabel
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@ast
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@en
P2093
P2860
P356
P1476
Conditional MHC class I ligand ...... cts HLA-A1, -A3, -A11, and -B7
@en
P2093
Arnold H Bakker
Boris Rodenko
Carsten Linnemann
Celia R Berkers
Mireille Toebes
Rieuwert Hoppes
Ton N M Schumacher
Wim J E van Esch
P2860
P304
P356
10.1073/PNAS.0709717105
P407
P577
2008-02-28T00:00:00Z